Thinking of joining a study?

Register your interest

NCT06771960 | RECRUITING | Lung Cancer (NSCLC)


Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Sponsor:

Guangdong Provincial People's Hospital

Information provided by (Responsible Party):

GUI bin Q iO

Brief Summary:

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.

Condition or disease

Lung Cancer (NSCLC)

Detailed Description:

Non-small cell lung cancer (NSCLC) with EGFR mutations represents a molecularly distinct subset of lung cancer that benefits from targeted therapies. Neoadjuvant targeted therapy has emerged as a promising approach for locally advanced NSCLC, aiming to achieve tumor downstaging and improve surgical outcomes. However, the prognostic significance of residual viable tumor (RVT) after neoadjuvant targeted therapy remains poorly understood. This retrospective study investigates the association between the percentage of RVT and survival outcomes in EGFR-mutated NSCLC patients following neoadjuvant targeted therapy. Specific survival outcomes were disease-free survival (DFS) and event-free survival (EFS). By highlighting RVT as a critical prognostic biomarker, the findings provide actionable insights for optimizing postoperative management and stratifying high-risk patients. This work underscores the need for pathological evaluation of RVT to refine prognosis and treatment strategies.

Study Type : OBSERVATIONAL
Estimated Enrollment : 120 participants
Official Title : Association Between Residual Viable Tumor and Prognosis After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-small Cell Lung Cancer
Actual Study Start Date : 2025-02-01
Estimated Primary Completion Date : 2025-12-01
Estimated Study Completion Date : 2025-12-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age 18-80 years old;
  • * Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
  • * Treated with neoadjuvant targeted therapy;
  • * Undergoing definitive surgery.
Exclusion Criteria
  • * A history of prior chemotherapy, immunotherapy, or radiotherapy.
  • * A history of malignancy or lung surgery;
  • * Missing key data.

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

Location Details

NCT06771960


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

China, Guangdong

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Loading...